PDF(Pubmed)
Abstract：
Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may cause a broad spectrum of dose-dependent cutaneous adverse events, including acneiform papulopustular rash, nail and hair disturbances, xerosis, and mucositis. The pathogenesis of the EGFR inhibitor-induced adverse reactions originates from disturbances in keratinocyte differentiation, cytokine secretion, and neutrophil chemotaxis. One of the rare, yet distressing adverse events may be folliculitis decalvans, a progressive neutrophil-driven scarring alopecia with hair tufts formation resembling doll\'s hair. Early diagnosis and introduction of treatment are crucial for disease prognosis since a long course of the disease leads to decreased quality of life. Here, we review the literature cases of EGFR inhibitor-induced folliculitis decalvans and provide guidance on management and prevention of this condition in oncologic patients. Furthermore, we report the first afatinib-associated folliculitis decalvans in three female patients with NSCLC.
摘要：
表皮生长因子受体(EGFR)是肿瘤学治疗上皮组织实体肿瘤的靶点之一。如非小细胞肺癌（NSCLC）和乳腺癌。用于癌症治疗的EGFR抑制剂可能会引起广谱的剂量依赖性皮肤不良事件，包括痤疮样丘疹脓疱疹，指甲和头发紊乱，干燥症,和粘膜炎。EGFR抑制剂诱导的不良反应的发病机制源于角质形成细胞分化的紊乱,细胞因子分泌，和中性粒细胞趋化性。一种罕见的，然而，令人痛苦的不良事件可能是毛囊炎decalvans，进行性中性粒细胞驱动的瘢痕性脱发，毛发簇绒形成类似于玩偶的毛发。早期诊断和引入治疗对于疾病预后至关重要，因为疾病的长期病程会导致生活质量下降。这里,我们回顾了EGFR抑制剂诱导的毛囊炎decalvans的文献病例,并就肿瘤患者的治疗和预防提供指导.此外，我们在3例女性NSCLC患者中报道了首例阿法替尼相关性毛囊炎。
